OLFML2A Overexpression Predicts an Unfavorable Prognosis in Patients with AML

Table 1

Association analysis between OLFML2A expression levels and clinicopathologic features in the TCGA-AML database.

Characteristic	Low expression of OLFML2A	High expression of OLFML2A	value
n	75	76
Gender, n (%)			1.000
Female	34 (22.5%)	34 (22.5%)
Male	41 (27.2%)	42 (27.8%)
Race, n (%)			1.000
Asian	0 (0%)	1 (0.7%)
Black or African American	6 (4%)	7 (4.7%)
White	67 (45%)	68 (45.6%)
Age, n (%)			0.211
≤60	48 (31.8%)	40 (26.5%)
>60	27 (17.9%)	36 (23.8%)
WBC count (×10^9/L), n (%)			0.191
≤20	43 (28.7%)	34 (22.7%)
>20	32 (21.3%)	41 (27.3%)
BM blasts (%), n (%)			0.444
≤20	27 (17.9%)	33 (21.9%)
>20	48 (31.8%)	43 (28.5%)
PB blasts (%), n (%)			0.372
≤70	39 (25.8%)	33 (21.9%)
>70	36 (23.8%)	43 (28.5%)
Cytogenetic risk, n (%)			0.035
Favorable	21 (14.1%)	10 (6.7%)
Intermediate	40 (26.8%)	42 (28.2%)
Poor	13 (8.7%)	23 (15.4%)
FAB classifications, n (%)			0.278
M0	6 (4%)	9 (6%)
M1	17 (11.3%)	18 (12%)
M2	23 (15.3%)	15 (10%)
M3	7 (4.7%)	8 (5.3%)
M4	14 (9.3%)	15 (10%)
M5	4 (2.7%)	11 (7.3%)
M6	2 (1.3%)	0 (0%)
M7	1 (0.7%)	0 (0%)
Cytogenetics, n (%)			0.014
Normal	32 (23.7%)	37 (27.4%)
+8	7 (5.2%)	1 (0.7%)
Del (5)	0 (0%)	1 (0.7%)
Del (7)	3 (2.2%)	3 (2.2%)
Inv (16)	8 (5.9%)	0 (0%)
t (15; 17)	5 (3.7%)	6 (4.4%)
t (8; 21)	4 (3%)	3 (2.2%)
t (9; 11)	0 (0%)	1 (0.7%)
Complex	7 (5.2%)	17 (12.6%)
FLT3 mutation, n (%)			0.005
Negative	59 (40.1%)	43 (29.3%)
Positive	14 (9.5%)	31 (21.1%)
IDH1 R132 mutation, n (%)			0.579
Negative	67 (45%)	69 (46.3%)
Positive	8 (5.4%)	5 (3.4%)
IDH1 R172 mutation, n (%)			0.245
Negative	72 (48.3%)	75 (50.3%)
Positive	2 (1.3%)	0 (0%)
IDH1 R140 mutation, n (%)			0.745
Negative	67 (45%)	70 (47%)
Positive	7 (4.7%)	5 (3.4%)
RAS mutation, n (%)			1.000
Negative	71 (47.3%)	71 (47.3%)
Positive	4 (2.7%)	4 (2.7%)
NPM1 mutation, n (%)			1.000
Negative	59 (39.3%)	58 (38.7%)
Positive	16 (10.7%)	17 (11.3%)